相关临床试验
52
7 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
3
5.8%
已完成
32
61.5%
尚未招募
4
7.7%
招募中
6
11.5%
暂停
1
1.9%
终止
5
9.6%
撤回
1
1.9%
暂无批准数据
- A phase 2 trial demonstrated that once-weekly oral islatravir plus lenacapavir maintained high rates of HIV viral suppression through 48 weeks in adults already suppressed on daily therapy. - The experimental weekly regimen achieved 94.2% viral suppression at week 24 and maintained efficacy through week 48, with no treatment-emergent resistance detected. - Safety profile was favorable with no treatment-related grade 3 or higher adverse events, and CD4+ T-cell counts remained stable throughout the study period. - The findings support continued evaluation in ongoing global phase 3 studies as a potential solution to address adherence challenges with daily HIV treatment.
- A comprehensive evaluation of eight widely advertised dietary supplements found none had strong independent clinical evidence supporting their marketed health claims, despite the $53 billion industry size. - Two popular supplements, Relief Factor and Nugenix products, had no available clinical research, while only Prevagen and Nutrafol showed limited evidence from randomized controlled trials. - Experts emphasize that current regulations don't require supplement companies to prove health claims through clinical trials, highlighting a significant gap in consumer protection.
